Phylogica Limited
PYC Therapeutics Limited, a development-stage biotechnology company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and VP-002, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on … Read more
Phylogica Limited (PH7) - Total Liabilities
Latest total liabilities as of June 2025: €13.27 Million EUR
Based on the latest financial reports, Phylogica Limited (PH7) has total liabilities worth €13.27 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Phylogica Limited - Total Liabilities Trend (2016–2025)
This chart illustrates how Phylogica Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Phylogica Limited Competitors by Total Liabilities
The table below lists competitors of Phylogica Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shandong Cynda Chemcial Co Ltd
SHG:603086
|
China | CN¥1.81 Billion |
|
Guangzhou Frontop Digital Creative Technology Co. Ltd. A
SHE:301313
|
China | CN¥672.52 Million |
|
Argosy Research
TWO:3217
|
Taiwan | NT$1.17 Billion |
|
BayCom Corp
NASDAQ:BCML
|
USA | $2.26 Billion |
|
Transcom Inc
TW:5222
|
Taiwan | NT$513.69 Million |
|
Yongji Printing Co Ltd
SHG:603058
|
China | CN¥599.22 Million |
|
Cartesian Growth Corporation III Unit
NASDAQ:CGCTU
|
USA | $13.54 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Phylogica Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Phylogica Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Phylogica Limited (2016–2025)
The table below shows the annual total liabilities of Phylogica Limited from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | €13.27 Million | +30.31% |
| 2024-06-30 | €10.18 Million | +16.75% |
| 2023-06-30 | €8.72 Million | +69.40% |
| 2022-06-30 | €5.15 Million | +28.20% |
| 2021-06-30 | €4.02 Million | +197.35% |
| 2020-06-30 | €1.35 Million | +236.12% |
| 2019-06-30 | €401.87K | -77.32% |
| 2018-06-30 | €1.77 Million | +18.97% |
| 2017-06-30 | €1.49 Million | +3.74% |
| 2016-06-30 | €1.44 Million | -- |